| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Aceragen, Inc. | CHIEF EXECUTIVE OFFICER, Director | Common Stock | 1,469,482 | $749,436 | $0.5100 | 17 Jan 2023 | Direct |
| Aceragen, Inc. | CHIEF EXECUTIVE OFFICER, Director | Stock Options (Right to Buy) | 74,500 | 20 Jan 2023 | Direct | ||
| Aceragen, Inc. | CHIEF EXECUTIVE OFFICER, Director | Series Z Convertible Preferred Stock | 0 | 17 Jan 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| /report/000141588923001854-taylor-john-clayton-2023-01-20 | Aceragen, Inc. | 20 Jan 2023 | 1 | $0 | 4 | CHIEF EXECUTIVE OFFICER, Director | 02 Feb 2023, 19:06 |
| /report/000110465923005133-taylor-john-clayton-2023-01-17 | Aceragen, Inc. | 17 Jan 2023 | 2 | $0 | 4 | Chief Executive Officer, Director | 19 Jan 2023, 20:45 |
| /report/000110465922104797-taylor-john-clayton-2022-09-28 | IDERA PHARMACEUTICALS, INC. | 28 Sep 2022 | 2 | $0 | 4 | Chief Executive Officer, Director | 30 Sep 2022, 21:49 |
| /report/000110465922104790-taylor-john-clayton-2022-09-28 | IDERA PHARMACEUTICALS, INC. | 28 Sep 2022 | 0 | $0 | 3 | Chief Executive Officer, Director | 30 Sep 2022, 21:45 |